Form 4 for ABOS Acumen Pharmaceuticals, Inc.

Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001209191-21-046031 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-07-08	2021-07-06	ABOS	Zuga Matt	CFO	C - Cnv Deriv	—	+26.2K	26.2K	New	—
DM	2021-07-08	2021-07-06	ABOS	Zuga Matt	CFO	C - Cnv Deriv	—	-26.2K	10.5K	-71%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-07-06	C	A	26,187	—	26,187	D	—	—	(F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
2	Derivative	Series A-1 Preferred Stock	2021-07-06	C	D	15,659	—	15,659	D	— · — to —	15,659 Common Stock	(F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
3	Derivative	Series B Preferred Stock	2021-07-06	C	D	10,528	—	10,528	D	— · — to —	10,528 Common Stock	(F1) On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.